ArticleEmerging microbes & infections2018
Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract.
Article in Emerging microbes & infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Global prevalence of mutation in theFrontiers in microbiology · 2024Pooled it
- Tetracyclines, a timely resurgence or doomed to fail again?Journal of medical microbiology · 2026Review
- Article
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Isolation and characterization of novel bacteriophages with broad-spectrum lytic activity against carbapenem-resistant Klebsiella pneumoniae capsular pathotypes K1, K2, K3, K5, and K20.Biology direct · 2026Article
- A novel ABC family protein participates in the regulation of fitness cost caused byFundamental research · 2026Article
- Emergence of Polymyxin Resistance Driven by a PhoQ Mutation in KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Resistance, Virulence, and Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2026Article
- The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae.npj antimicrobials and resistance · 2025Review
- Genomic epidemiology and anti-biofilm mechanisms of Lactobacillus in ST11 carbapenem-resistantFrontiers in microbiology · 2025Article
- Deciphering the gastrointestinal carriage ofInfection and immunity · 2024Review
- Article
- Virulence Factors and Carbapenem-Resistance Mechanisms in HypervirulentInfection and drug resistance · 2024Review
- Genomic and functional characterization of carbapenem-resistant Klebsiella pneumoniae from hospital wastewater.BMC microbiology · 2023Article
- Role of the ISKpn element in mediating mgrB gene mutations in ST11 hypervirulent colistin-resistantFrontiers in microbiology · 2023Article
- Review
- Klebsiella pneumoniae l-Fucose Metabolism Promotes Gastrointestinal Colonization and Modulates Its Virulence Determinants.Infection and immunity · 2022Article
- Prevalence and Molecular Typing of Carbapenemase-Producing Enterobacterales among Newborn Patients in Italy.Antibiotics (Basel, Switzerland) · 2022Article
- Isolation, Molecular Characterization, and Antimicrobial Resistance of Selected Culturable Bacteria From Crayfish (Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) strains that also exhibit resistance to tigecycline and colistin have become a major clinical concern, as these two agents are the last-resort antibiotics used for treatment of CRKP infections. A leukemia patient infected with CRKP was subjected to follow-up analysis of variation in phenotypic and genotypic characteristics of CRKP strains isolated from various specimens at different stages of treatment over a period of 3 years. Our data showed that (1) carbapenem treatment led to the emergence of CRKP in the gastrointestinal (GI) tract of the patient, which subsequently caused infections at other body sites as well as septicemia; (2) treatment with tigecycline led to the emergence of tigecycline-resistant CRKP, possibly through induction of the expression of a variant tet(A) gene located in a conjugative plasmid; (3) colistin treatment was effective in clearing CRKP from the bloodstream but led to the emergence of mcr-1-positive Enterobacteriaceae strains as well as colistin-resistant CRKP in the GI tract due to inactivation of the mgrB gene; and (4) tigecycline- and colistin-resistant CRKP could persist in the human GI tract for a prolonged period even without antibiotic selection pressure. In conclusion, clinical CRKP strains carrying a conjugative plasmid that harbors the bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.